| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Concise Review |
a Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA;
b Mirus Corporation, Madison, Wisconsin, USA
Key Words. Autoimmune diabetes • Allogeneic chimerism • NOD mouse
Tatiana D. Zorina, M.D., Ph.D., Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh, School of Medicine, 3460 Fifth Avenue, Rangos Research Center, Pittsburgh, Pennsylvania, USA 15213. Telephone: 412-692-5238; Fax: 412-692-5809; e-mail: tatiana{at}pitt.edu
In light of accumulating evidence that the endocrine pancreas has regenerative properties and that hematopoietic chimerism can abrogate destruction of ß cells in autoimmune diabetes, we addressed the question of whether recovery of physiologically adequate endogenous insulin regulation could be achieved in the nonobese diabetic (NOD) mice rendered allogeneic chimerae. Allogeneic bone marrow (BM) was transplanted into NOD mice at the preclinical and overtly clinical stages of the disease using lethal and nonlethal doses of radiation for recipient conditioning. Islets of Langerhans, syngeneic to the BM donors, were transplanted under kidney capsules of the overtly diabetic animals to sustain euglycemia for the time span required for recovery of the endogenous pancreas. Nephrectomies of the graft-bearing organs were performed 14 weeks later to confirm the restoration of endogenous insulin regulation. Reparative processes in the pancreata were assessed histologically and immunohistochemically. The level of chimerism in NOD recipients was evaluated by flow cytometric analysis. We have shown that as low as 1% of initial allogeneic chimerism can reverse the diabetogenic processes in islets of Langerhans in prediabetic NOD mice, and that restoration of endogenous ß cell function to physiologically sufficient levels is achievable even if the allogeneic BM transplantation is performed after the clinical onset of diabetes. If the same pattern of islet regeneration were shown in humans, induction of an autoimmunity-free status by establishment of a low level of chimerism, or other alternative means, might become a new therapy for type 1 diabetes.
This article has been cited by other articles:
|
|
 |
|
  B. Phillips, K. Nylander, J. Harnaha, J. Machen, R. Lakomy, A. Styche, K. Gillis, L. Brown, D. Lafreniere, M. Gallo, et al. A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes Diabetes, June 1, 2008; 57(6): 1544 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. Urban, J. Kiss, J. Kovacs, E. Gocza, V. Vas, E. Monostori, and F. Uher Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes Stem Cells, January 1, 2008; 26(1): 244 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. ABLAMUNITS, N. A. SHERRY, J. A. KUSHNER, and K. C. HEROLD Autoimmunity and beta Cell Regeneration in Mouse and Human Type 1 Diabetes: The Peace Is Not Enough Ann. N.Y. Acad. Sci., April 1, 2007; 1103(1): 19 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yin, J. Tao, D. D. Lee, J. Shen, M. Hara, J. Lopez, A. Kuznetsov, L. H. Philipson, and A. S. Chong Recovery of Islet {beta}-Cell Function in Streptozotocin- Induced Diabetic Mice: An Indirect Role for the Spleen Diabetes, December 1, 2006; 55(12): 3256 - 3263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Narang and R. I. Mahato Biological and biomaterial approaches for improved islet transplantation. Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bottino and M. Trucco Multifaceted Therapeutic Approaches for a Multigenic Disease Diabetes, December 1, 2005; 54(suppl_2): S79 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Suarez-Pinzon, Y. Yan, R. Power, S. J. Brand, and A. Rabinovitch Combination Therapy With Epidermal Growth Factor and Gastrin Increases {beta}-Cell Mass and Reverses Hyperglycemia in Diabetic NOD Mice Diabetes, September 1, 2005; 54(9): 2596 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sordi, M. L. Malosio, F. Marchesi, A. Mercalli, R. Melzi, T. Giordano, N. Belmonte, G. Ferrari, B. E. Leone, F. Bertuzzi, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets Blood, July 15, 2005; 106(2): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Askenasy, E. S. Yolcu, I. Yaniv, and H. Shirwan Induction of tolerance using Fas ligand: a double-edged immunomodulator Blood, February 15, 2005; 105(4): 1396 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kodama, M. Davis, and D. L. Faustman Diabetes and Stem Cell Researchers Turn to the Lowly Spleen Sci. Aging Knowl. Environ., January 19, 2005; 2005(3): pe2 - pe2. [Abstract] [Full Text]
|
|
|
|
|
|
N. Ogawa, J. F. List, J. F. Habener, and T. Maki Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4 Diabetes, July 1, 2004; 53(7): 1700 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Q. Tang, L.-Z. Cao, B. R. Burkhardt, C.-Q. Xia, S. A. Litherland, M. A. Atkinson, and L.-J. Yang In Vivo and In Vitro Characterization of Insulin-Producing Cells Obtained From Murine Bone Marrow Diabetes, July 1, 2004; 53(7): 1721 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Q. Daley, M. A. Goodell, and E. Y. Snyder Realistic Prospects for Stem Cell Therapeutics Hematology, January 1, 2003; 2003(1): 398 - 418. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
